PWM
CORT icon

Parkworth Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Parkworth Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$220 Hold
3
– – ﹤0.01% 916
2025
Q1 		$343 Hold
3
– – ﹤0.01% 542
2024
Q4 		$151 Buy
+3
New +$157 ﹤0.01% 854

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkworth Wealth Management's CORT Position: Q2 2025 in Review

Parkworth Wealth Management held its Corcept Therapeutics (CORT) position steady in Q2 2025 at 3 shares worth $220. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Parkworth Wealth Management first reported a position in CORT in Q4 2024 and has held it in 3 quarters since. The position peaked at $343 in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Parkworth Wealth Management held 3 shares of Corcept Therapeutics worth $220 as of Q2 2025.
  • Parkworth Wealth Management left its Corcept Therapeutics share count unchanged in Q2 2025.
  • Corcept Therapeutics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #916 holding.
  • Parkworth Wealth Management first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's Corcept Therapeutics position peaked at $343 in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.